Table 1.
Summary of selected preclinical gene therapy studies
| Target | Model | Transgene | Study | End point |
|---|---|---|---|---|
| Peripheral vascular disease | HLI, rabbit | VEGF and bFGF | Kondoh et al. (2004) | Combination effective for collaterals |
| HLI, rabbit | bFGF | Ishii et al. (2004) | Significant collateralisation | |
| HLI, rabbit | VEGF165 and Ang-1 | Ohara et al. (2001) | Significant neovascularisation | |
| HLI, mouse | VEGF121, -165, -189 | Whitlock et al. (2004) | Combination effective | |
| Myocardial ischaemia | Ameroid LCCA, pig | VEGF165 | Laguens et al. (2002) | Increased cariomyocyte mitosis |
| Ameroid LCCA, mini-swine | VEGF165 | Zhang et al. (2002) | Decreased ischaemia area and increased collaterals | |
| Stress, pig | FGF4 | Gao et al. (2004) | No toxic effects | |
| Ameroid LCCA pig | HIFα | Heinl-Green et al. (2005) | Increased perfusion | |
| Neointimal hyperplasia | Vascular graft, pig | TIMP-3 | Akowuah et al. (2005) | Increased luminal area |
| Vascular graft, rat | Antisense TGF | Wolff et al. (2005) | Reduced neointimal hyperplasia | |
| Vascular graft, rabbit | NOS | West et al. (2001) | Reduced neointimal hyperplasia | |
| Vascular graft, pig | p53 | Wan et al. (2004) | Reduced neointimal hyperplasia | |
| PTA and stent, rat | iNOS | Fishbein et al. (2006) | Reduced ISR | |
| PTA and stent, pig | TIMP-3 | Johnson et al. (2005) | Reduced ISR | |
| PTCA and stent, rabbit | VEGF-2 | Walter et al. (2004) | Reduced ISR and increased RE |
Abbreviations: bFGF, basic fibroblast growth factor; HIFα, hypoxia-inducible factor α; HLI, hindlimb ischaemia; iNOS, inducible nitric oxide synthase; ISR, in-stent restenosis; LCCA, ameroid constrictor placed on the left circumflex artery; NOS, nitric oxide synthase; PTA, percutaneous transluminal angioplasty; RE, re-endothelialisation; TGF, tissue growth factor; TIMP-3, tissue inhibitor of matrix metalloproteinase-3; VEGF, vascular endothelial growth factor.